中国医药报
长期控制慢性乙肝成为现实

2009.02.19
_________________________________________________________________________________________
Summary:Bristol-Myers Squibb Company announced data from 2 studies at the 19th APASL. Data showed that 96% chronic hepatitis B patients with 3~7 years of treatment of entecavir achieved undetedctable viral load. Meanwhile, patients also experienced improvement in liver histology. Academician Zhuang Hui from the Chinese Academy of Engineering said that it is no longer a wild wish to control chronic hepatitis B for a long time with the antivirus agents in nucleotide

2009.02.19
_________________________________________________________________________________________
内容摘要：据百时美施贵宝公司介绍，新近完成的编号为ETV901和ETV060的研究显示，慢性乙肝患者在接受3~7年的恩替卡韦治疗期间，96%的患者乙肝病毒载量降到不可测水平。同时，患者的肝脏炎症得到显著改善，肝纤维化明显减退或完全逆转，延缓了病情进展。中国工程院院士庄辉对此评价：“这表明，使用核苷类抗病毒药物长期控制慢性乙肝不再是奢望。”这两项研究的结果已在日前召开的亚太肝病学会第十九届年会上正式公布

点击小图看大图